awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q45983415-6AC4ABCF-4814-43D4-99AC-AB468C34A68B
Q45983415-6AC4ABCF-4814-43D4-99AC-AB468C34A68B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q45983415-6AC4ABCF-4814-43D4-99AC-AB468C34A68B
Safety and Efficacy of Apremilast Through 104 Weeks in Patients With Moderate to Severe Psoriasis Who Continued on Apremilast or Switched From Etanercept Treatment: Findings From the LIBERATE Study.
P2860
Q45983415-6AC4ABCF-4814-43D4-99AC-AB468C34A68B
BestRank
Statement
http://www.wikidata.org/entity/statement/Q45983415-6AC4ABCF-4814-43D4-99AC-AB468C34A68B
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
d1f3b4b275e77e2d60c002d0c40b37bcadf3c9d9
P2860
The efficacy and safety of apremilast, etanercept and placebo in patients with moderate-to-severe plaque psoriasis: 52-week results from a phase IIIb, randomized, placebo-controlled trial (LIBERATE)